Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Urinary DNA-methylation and protein biomarkers identify urothelial carcinoma among other genitourinary diseases and cancer-free individuals.
Lang K, Köhler CU, Wichert K, Deix T, Bartsch G, Sommer G, Lübke C, Roghmann F, Reike MJ, Krentel H, Engellandt K, Schiermeier S, Menke V, Noldus J, Behrens T, Brüning T, Käfferlein HU. Lang K, et al. Among authors: roghmann f. J Transl Med. 2024 Nov 26;22(1):1061. doi: 10.1186/s12967-024-05844-x. J Transl Med. 2024. PMID: 39587670 Free PMC article.
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS; NIAGARA Investigators. Powles T, et al. Among authors: roghmann f. N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282910 Clinical Trial.
[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].
Niegisch G, Bolenz C, Doehn C, Gakis G, Hartmann A, Müller-Huesmann H, Reis H, Roghmann F, Schwamborn K, Tiemann K, Retz M. Niegisch G, et al. Among authors: roghmann f. Urologie. 2024 Oct;63(10):1019-1027. doi: 10.1007/s00120-024-02416-1. Epub 2024 Aug 26. Urologie. 2024. PMID: 39186130 Free PMC article. Review. German.
Retraction: Tobacco-specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer.
Jin F, Thaiparambil J, Donepudi SR, Vantaku V, Piyarathna DWB, Maity S, Krishnapuram R, Putluri V, Gu F, Purwaha P, Bhowmik SK, Ambati CR, von Rundstedt FC, Roghmann F, Berg S, Noldus J, Rajapakshe K, Gödde D, Roth S, Störkel S, Degener S, Michailidis G, Kaipparettu BA, Karanam B, Terris MK, Kavuri SM, Lerner SP, Kheradmand F, Coarfa C, Sreekumar A, Lotan Y, El-Zein R, Putluri N. Jin F, et al. Among authors: roghmann f. Cancer Prev Res (Phila). 2024 Jun 4;17(6):281. doi: 10.1158/1940-6207.CAPR-24-0164. Cancer Prev Res (Phila). 2024. PMID: 38831722 No abstract available.
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.
Grimm MO, Schostak M, Grün CB, Loidl W, Pichler M, Zimmermann U, Schmitz-Dräger B, Steiner T, Roghmann F, Niegisch G, Bolenz C, Schmitz M, Baretton G, Leucht K, Schumacher U, Foller S, Zengerling F, Meran J; TITAN-TCC Study Group. Grimm MO, et al. Among authors: roghmann f. JAMA Oncol. 2024 Jun 1;10(6):755-764. doi: 10.1001/jamaoncol.2024.0938. JAMA Oncol. 2024. PMID: 38722641 Clinical Trial.
Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor.
Haas M, Kriegmair MC, Breyer J, Sikic D, Wezel F, Roghmann F, Brehmer M, Wirtz RM, Jarczyk J, Erben P, Bahlinger V, Goldschmidt F, Fechner G, Chen J, Paxinos E, Bates M, Zengerling F, Bolenz C, Burger M, Hartmann A, Eckstein M. Haas M, et al. Among authors: roghmann f. BJU Int. 2024 Nov;134(5):755-762. doi: 10.1111/bju.16389. Epub 2024 May 8. BJU Int. 2024. PMID: 38717014
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M. Klümper N, et al. Among authors: roghmann f. J Clin Oncol. 2024 Jul 10;42(20):2446-2455. doi: 10.1200/JCO.23.01983. Epub 2024 Apr 24. J Clin Oncol. 2024. PMID: 38657187 Free PMC article.
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.
Pal SK, Grivas P, Gupta S, Dizman N, Zengin Z, Valderrama BP, Rodriguez-Vida A, Roghmann F, Sevillano Fernandez E, Matin SF, Loriot Y, Sridhar SS, Sonpavde G, Fleming MT, Lerner SP, Bellmunt J, Master V, Tripathi A, Davis K, van Veenhuyzen D, Weng R, Daneshmand S. Pal SK, et al. Among authors: roghmann f. Eur Urol. 2024 Apr 4:S0302-2838(24)02247-4. doi: 10.1016/j.eururo.2024.03.023. Online ahead of print. Eur Urol. 2024. PMID: 38580518 No abstract available.
167 results